LncRNAs in Immune and Stromal Cells Remodel Phenotype of Cancer Cell and Tumor Microenvironment
DOI: https://doi.org/10.2147/jir.s460730
IF: 4.5
2024-05-18
Journal of Inflammation Research
Abstract:Wenbin Li, 1, 2, &ast Haohan Zhang, 3, &ast Zuo You, 4 Baozhu Guo 5 1 Department of Clinical Oncology, Qianjiang Hospital Affiliated to Renmin Hospital of Wuhan University, Qianjiang, Hubei, People's Republic of China; 2 Department of Clinical Oncology, Qianjiang Central Hospital of Hubei Province, Qianjiang, Hubei, People's Republic of China; 3 Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China; 4 Department of Traditional Chinese Medicine, Xianfeng County People's Hospital, Enshi, Hubei, People's Republic of China; 5 Department of Pain, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zuo You, Department of Traditional Chinese Medicine, Xianfeng County People's Hospital, Enshi, 445600, People's Republic of China, Email Baozhu Guo, Department of Pain, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China, Email Emerging studies suggest that long non-coding RNAs (lncRNAs) participate in the mutual regulation of cells in tumor microenvironment, thereby affecting the anti-tumor immune activity of immune cells. Additionally, the intracellular pathways mediated by lncRNAs can affect the expression of immune checkpoints or change the cell functions, including cytokines secretion, of immune and stromal cells in tumor microenvironment, which further influences cancer patients' prognosis and treatment response. With the in-depth research, lncRNAs have shown great potency as a new immunotherapy target and predict immunotherapy response. The research on lncRNAs provides us with a new insight into developing new immunotherapy drugs and predicting the outcome of immunotherapy. With development of RNA sequencing technology, amounts of lncRNAs were found to be dysregulated in immune and stromal cells rather than tumor cells. These lncRNAs function through ceRNA network or regulating transcript factor activity, thus leading abnormal differentiation and activation of immune and stromal cells. Here, we review the function of lncRNAs in the immune microenvironment and focus on the alteration of lncRNAs in immune and stromal cells, and discuss how these alterations affect tumor growth, metastasis and treatment response. Keywords: lncRNA, immune and stromal cells, tumor microenvironment, differentiation, cytokine secretion At present, cancer poses the highest clinical, social, and economic burden in terms of cause-specific Disability-Adjusted Life Years among all human diseases. 1 The cellular environment, in which tumor cells are located, referred as tumor microenvironment (TME), steps into the limelight since its importance in cancer incidence, progress and treatment response. 2 In TME, the infiltration and function of immune and stromal cells were reprogrammed via multiple ways. The growth-promoting signals and intermediate metabolites were released to remodeling the tissue structure to build a suitable environment for tumor progression and metastasis. 3 By interacting with the microenvironment, tumor cells acquire more vigorous proliferation and metastasis capabilities. 4 Moreover, immune escape in tumor microenvironment has been indicated a treating target of cancers. For instance, immunotherapy recovers activity of exhausted CD8+ T cells to suppress tumor cells. 5 However, the pivotal elements and pathways of immune tolerance in TME were still obscure. Long noncoding RNA (lncRNA) is a non-protein coding RNA with more than 200 nucleotides. LncRNAs were reported to regulate shearing, transposon silencing, and mRNA translation. 6 In cancer cells, several oncogenic lncRNAs were shown to promote the progression of cancer by competitively binding miRNAs. For instance, the downregulation of the oncogenic lncRNA MALAT-1 was shown to suppress the expression of immune-suppressive cytokines, 7,8 and the lncRNA CCAT1 and H19 were reported to target PD-L1 expression in cancer cell lines. 9,10 In TME, lncRNAs can act as intermediaries between tumor cells and other cells through exosomes and regulate immune cell function through intracellular pathways, such as PD-1/PD-L1 pathway, a major target of immunotherapy in cancers. 11,12 Previous studies have suggested that lncRNAs exhibit a non-negligible effect on the formation of immune suppression in the immune microenvironment 13 and can be used as targets to relieve immunosuppression to predict the efficacy of immunotherapy. 14 However, previous studies mainly focused on lncRNAs or exosomes derived from tumor cell, relatively ignoring the dysregulation of lncRNAs in -Abstract Truncated-
immunology